ECO Animal Health Group plc (AIM: EAH)

Market Cap	44.72M
Revenue (ttm)	89.42M
Net Income (ttm)	1.05M
Shares Out	67.76M
EPS (ttm)	0.02
PE Ratio	43.42
Forward PE	42.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,489
Open	62.60
Previous Close	65.00
Day's Range	62.60 - 66.69
52-Week Range	62.60 - 135.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1972
• Employees: 227
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EAH

Financial Performance

In 2023, ECO Animal Health Group's revenue was 89.42 million, an increase of 4.82% compared to the previous year's 85.31 million. Earnings were 1.05 million, an increase of 3.97%.